ADVERTISEMENT

‘3D drugs promise early cure with no side effects’

Published - November 28, 2018 12:54 am IST - ONGOLE

The tech can also create implantable delivery devices, says expert

Frontier research: Dr.G.Himabindu being felicitated by RIMS Director Sk. Mastan Saheb and Pharmacology Department head Solomon Raj, in Ongole on Tuesday.

A patient may soon get customised drugs for an early cure without side effects thanks to 3D-printing technology, according to Dr.G.Himabindu of the Rajiv Gandhi Institute of Medical Sciences here.

Returning from Rome, where she delivered a keynote address at an international conference on ‘Euro Global Congress on Pharma and Clinical trials’ from November 14 to 16, she told the media here on Tuesday that the new technology makes drug delivery safe and more potent.

A pharmacist could print and dispense personalised medication through an automated 3D printing system and the dosage can be adjusted based on clinical response, said Dr. Himabindu, Assistant Professor in Pharmacology at RIMS. Implantable drug delivery devices with novel drug release profiles could also be created using 3D printing, she explained. A person suffering from pancreatic cancer could be effectively treated by using the technology without side effects, she added.

ADVERTISEMENT

‘Polypill a boon’

Dr.Himbabindu, who has specialised in geriatrics, said polypill would be a boon for the elderly suffering from hypertension and type-2 diabetes. A high drug load could be delivered in a single dose using ZipDose Technology, she said, adding 3D printed drug, Spritam, was now available to treat epilepsy.

Dr.Himabindu, who also presented a paper on minimising adverse drug reactions in older adults, was felicitated by a RIMS team of doctors led by its Director Sk. Mastan Saheb.

ADVERTISEMENT

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT